Lead Product(s) : Oligonucleotide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Immunalgia Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Pharmacokinetics of IMT504, an Immunomodulator and Tissue Repair Inducer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 15, 2024
Lead Product(s) : Oligonucleotide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Immunalgia Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable